Rationale for the use of Azithromycin as Mycobacterium avium Chemoprophylaxis

American Journal of Medicine

Volumn 102, Issue 5 C, 1997, Pages 37-49

  Dunne, Michael W ^a   Foulds, George ^a   Retsema, James A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CYTOCHROME P450;

AREA UNDER THE CURVE; ARTICLE; CHEMOPROPHYLAXIS; DRUG ACTIVITY; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG ALVEOLUS MACROPHAGE; LYMPHOCYTE COUNT; LYSOSOME; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL;

EID: 0030842456     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00043-0     Document Type: Article

References (110)

1. Wu M, Kolonski P, Yamada J, Inderlied C, Young LS. Program Abstract of the 27th Interscience Conference. (Abstr.). Antimicrob Agents Chemother. 564:1987;194.
2. Bright GM, Nagel AA, Bordner J, et al. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. J Antibiot. 41:1988;1029-1047.
3. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother. 31:1987;1939-1947.
4. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother. 34:1990;1056-1060.
5. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 25:((suppl A)):1990;73-82.
6. Gardner MJ, Ronfeld RA. Interpretation/characterization of the pharmacokinetics of azithromycin in man. (Abstr. 407.) 8th Mediterranean Congress of Chemotherapy, Athens, Greece, 1992.
7. Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother. 31:((suppl E)):1993;39-50.
8. Gladue RP, Bright GM, Issacson RI, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 33:1989;277-282.
9. Wildfeuer A, Laufen H, Muller-Wenig D, Haferkamp O. Interaction of azithromycin and human phagocytic cells. Arzneimittelforschung. 39:1989;755-758.
10. Bonnet M, Van der Auwera P. In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62,993) and its influence on ex vivo leukocyte chemiluminescence. Antimicrob Agents Chemother. 36:1992;1302-1309.
11. Panteix G, Guillaumond B, Harf R. In-vitro concentration of azithromycin in human phagocytic cells. J Antimicrob Chemother. 31:((suppl E)):1993;1-4.
12. Wildfeuer A, Reisert I, Laufen H. Uptake and subcellular distribution of azithromycin in human phagocytic cells. Arzneimittelforschung. 43:1993;484-486.
13. Carlier MB, Garcia-Luque I, Montenez JP, Tulkens PM, Piret J. Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int J Tissue React. 16:1994;211-220.
14. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. Azithromycin concentrations at the sites of pulmonary infection. Eur Resp J. 3:1990;886-890.
15. Wildfeuer A, Laufen H, Zimmermann T. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob Agents Chemother. 40:1996;75-79.
16. Wildfeuer A, Laufen H, Zimmermann T. Distribution of orally administered azithromycin in various blood compartments. Int J Clin Pharmacol Ther. 32:1994;356-360.
17. Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother. 40:1996;2375-2379.
18. Olsen KM, San Pedro GS, Gann LP, Gubbins PO, Halinski DH, Campbell GD Jr. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimocrob Agents Chemother. 40:1996;2582-2585.
19. Foulds G, Vincent J, Willavize SA, Johnson AC, Sweet D. The clinical pharmacology of azithromycin (AZM) in HIV+ subjects. (Abstr. 300.) 34th Annual Meeting of the Infectious Disease Society of America, New Orleans, LA, 1996.
20. Bermudez LE, Inderlied C, Young LS. Stimulation with cytokines enhances penetration of azithromycin into human macrophages. Antimicrob Agents Chemother. 35:1991;2625-2629.
21. Shepard RM, Amacher DE, Mullins MA, et al. Mechanism of azithromycin tissue uptake and accumulation: subcellular localization of azithromycin in rat liver. (Abstr. 217.) 1st International Conference on Macrolides, Azalides and Streptogramins, Santa Fe, NM, 1992.
22. Girard AE, Girard D, English AR, et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother. 31:1987;1948-1954.
23. Girard AE, Girard D, Retsema JA. Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection. J Antimicrob Chemother. 25:((suppl A)):1990;61-71.
24. Fitzgeorge RB, Lever S, Baskerville A. A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease. J Antimicrob Chemother. 31:((suppl E)):1993;171-176.
25. Beale AS, Upshon PA. Characteristics of murine model of genital infection with Chlamydia trachomatis and effects of therapy with tetracyclines, amoxicillin-clavulanic acid or azithromycin. Antimicrob Agents Chemother. 38:1994;1937-1943.
26. Stamler DA, Edelstein MA, Edelstein PH. Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages. Antimicrob Agents Chemother. 38:1994;217-222.
27. Retsema JA, Girard AE, Girard D, Milisen WB. Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo. J Antimicrob Chemother. 25:((suppl A)):1990;83-89.
28. Goldman RC, Fesik SW, Doran CC. Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 34:1990;426-431.
29. Capobianco JO, Goldman RC. Erythromycin and azithromycin transport into Haemophilus influenzae ATCC 19418 under conditions of depressed proton motive force (Æ μH ). Antimicrob Agents Chemother. 34:1990;1787-1791.
30. Moazed D, Noller HF. Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochimie. 69:1987;879-884.
31. Meier A, Kirschner P, Springer B, et al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother. 38:1994;381-384.
32. Inderlied CB. Antimycobacterial susceptibility testing: present practices and future trends. Eur J Clin Microbiol Infect Dis. 13:1994;980-993.
33. Ollar RA, Brown S, Dale JW, Felder MS. A modified broth dilution assay for antibiotic sensitivity testing of Mycobacterium avium-intracellulare using paraffin slide cultures. Tubercle. 72:1991;198-205.
34. Inderlied CB, Kolonoski PT, Wu M, Young LS. In vitro and in vivo activity of azithromycin (CP-62,993) against the Mycobacterium avium complex. J Infect Dis. 159:1989;994-997.
35. Naik S, Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother. 33:1989;1614-1616.
36. Yew WW, Piddock LJ, Li MS, Lyon D, Chan CY, Cheng AF. In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother. 34:1994;343-351.
37. Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother. 37:1993;2364-2370.
38. Cynamon MH, Klemens SP, Grossi MP. Comparative activities of azithromycin and clarithromycin against Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother. 38:1994;1452-1454.
39. Retsema JA, Brennan LA, Girard AE. Effects of environmental factors on the in vitro potency of azithromycin. Eur J Clin Microbiol Infect Dis. 10:1991;834-841.
40. Barry AL, Fuchs PC. Influence of the test medium on azithromycin and erythromycin and erythromycin regression statistics. Eur J Clin Microbiol Infect Dis. 10:1991;846-849.
41. Truffot-Pernot C, Ji B, Grosset J. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother. 35:1991;1677-1678.
42. Heifets LB, Lindholm-Levy PJ, Comstock RD. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis. 145:1992;856-858.
43. Bernard EM, Edwards FF, Kiehn TE, Brown ST, Armstrong D. Activities of antimicrobial agents against clinical isolates of Mycobacterium haemophilum. Antimicrob Agents Chemother. 37:1993;2323-2326.
44. Brown BA, Wallace RJ Jr, Onyi GI, DeRosas G, Wallace RJ III. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae and M. chelonae-like organisms. Antimicrob Agents Chemother. 36:1992;180-184.
45. Witzig R, Franzblau SG. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid. Antimicrob Agents Chemother. 37:1993;1997-1999.
46. Franzblau SG, Hastings RC. In vitro and in vivo activities of macrolides against Mycobacterium leprae. Antimicrob Agents Chemother. 32:1988;1758-1762.
47. Gelber RH, Siu P, Tsang M, Murray LP. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. Antimicrob Agents Chemother. 35:1991;760-763.
48. Watt B, Rayner A, Harris G. Comparative activity of azithromycin against clinical isolates of mycobacteria. J Antimicrob Chemother. 38:1996;539-542.
49. Inderlied CB, Kemper CA, Bermudez LE. The Mycobacterium avium complex. Clin Microbiol Rev. 6:1993;266-310.
50. Orme IM, Roberts AD, Furney SK, Skinner PS. Animal and cell-culture models for the study of mycobacterial infections and treatment. Eur J Clin Microbiol Infect Dis. 13:1994;994-999.
51. Perronne C, Gikas A, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother. 35:1991;1356-1359.
52. Bermudez LE, Young LS. Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. Antimicrob Agents Chemother. 32:1988;1149-1153.
53. Gevaudan MJ, Bollet C, Mallet MN, Gulian G, Tissot-Dupont H, de Micco P. Activity of azithromycin and roxithromycin alone or in combination against Mycobacterium avium and Mycobacterium xenopi. Pathol Biol. 38:1990;413-419.
54. Onyeji CO, Nightingale CH, Nicolau DP, Quintiliani R. Activities of liposome-encapsulated azithromycin and rifabutin compared with that of clarithromycin against Mycobacterium avium-intracellulare complex in human macrophages. Int J Antimicrob Agents. 4:1994;281-289.
55. Shiralsuchi H, Edmonds K, Jacobs MR, Klopman G, Ellner JJ. Differences in the activity of fluoroquinolones and azalides against Mycobacterium avium in cell free systems and as intracellular organisms within human monocytes. (Abstr. 1347.) 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993.
56. Bermudez LE, Martinelli J, Petrofsky M, Kolonoski P, Young LS. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effect of antibiotics against Mycobacterium avium complex infection in the beige mouse model. J Infect Dis. 169:1994;575-580.
57. Crowle AJ, Dahl R, Ross E, May MH. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect Immun. 59:1991;1823-1831.
58. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science. 263:1994;678-681.
59. Bermudez LE, Petrofsky M, Young LS. Azithromycin (AZM) for prophylaxis of disseminated M. avium complex (MAC) infection in mice. (Abstr. 1667.) 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992.
60. Brown ST, Edwards FF, Bernard EM, Tong W, Armstrong D. Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine. Antimicrob Agents Chemother. 37:1993;398-402.
61. Kolonoski PT, Wu M, Inderlied CB, Young LS. Azithromycin (AZM) ethambutol (EBM) and sparfloxacin (SP) for disseminated M. avium complex (MAC) infection in C7 beige mice. (Abstr. 1666.) 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992.
62. Cynamon MH, Klemens SP. Activity of azithromycin against Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother. 36:1992;1611-1613.
63. Klemens SP, Cynamon MH. Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother. 38:1994;1721-1725.
64. Klemens SP, Grossi MA, Cynamon MH. Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex. Antimicrob Agents Chemother. 38:1994;234-237.
65. Gangadharam PR. Beige mouse model for Mycobacterium avium complex disease. Antimicrob Agents Chemother. 39:1995;1647-1654.
66. Nash KA, Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother. 39:1995;2625-2630.
67. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Selection or resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob Agents Chemother. 36:1992;2839-2840.
68. Nash KA, Inderlied CB. Rapid detection of mutations associated with macrolide resistance in Mycobacterium avium complex. Antimicrob Agents Chemother. 40:1996;1748-1750.
69. Bermudez LE, Petrofsky M, Kolonoski P, Young LS. Emergence of Mycobacterium avium (MAC) populations resistant to macrolides during experimental chemotherapy. (Abstr. C145.) 36th Interscience Conference on Antimicrobial Agent and Chemotherapy, New Orleans, LA, 1996.
70. Oldfield EC, Dickinson G, Chung R, et al. Once weekly azithromycin for the prevention of Mycobacterium avium complex (MAC) infection in AIDS patients. (Abstr. 203.) 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.
71. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med. 335:1996;392-398.
72. Klemens SP, Cynamon MH. Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice. Antimicrob Agents Chemother. 38:1994;1455-1459.
73. Shepard RM, Falkner FC. Pharmacokinetics of azithromycin in rats and dogs. J Antimicrob Chemother. 25:((suppl A)):1990;49-60.
74. Shepard RM, Duthu GS, Ferraina RA, Mullins MA. High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissues. J Chromatogr A. 565:1991;321-337.
75. Nibbering PH, Zomerdijk TP, Corsel-Van Tilburg AJ, Van Furth R. Mean cell volume of human blood leucocytes and resident and activated murine macrophages. J Immunol Methods. 129:1990;143-145.
76. Molinari G, Paglia P, Shito GC. Inhibition of motility of pseudomonas aeruginosa and proteus mirabilis by subinhibitory concentrations of azithromycin. Eur J Clin Microbiol Infect Dis. 11:1992;469-471.
77. Braga PC, Piatti G. Interference by subinhibitory concentrations of azithromycin with the mechanism of bacterial adhesion to human epithelial cells. Chemother. 39:1993;432-437.
78. Minguez F, Ramos C, Loscos A, Chiu ML, Prieto J. In vitro killing kinetics and postantibiotic effect of josamycin and other macrolides on several bacteria. Chemother. 39:1993;163-168.
79. Fang GD, Stout JE, Yu VL. Comparison of intracellular postantibiotic effect (PAE) of azithromycin (Azith) and clarithromycin (Clari) vs. erythromycin (Eryth) against Legionella pneumophila serogroup 1 (LP1). (Abstr. A91.) 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996.
80. Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother. 35:1991;1186-1190.
81. Felstead S. Azithromycin drug interactions. Pathol Biol. 43:1995;512-514.
82. von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf. 13:1995;105-122.
83. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet. 23:1992;106-131.
84. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother. 37:((suppl C)):1996;133-142.
85. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother. 29:1995;906-917.
86. Flaherty J, Halle LG, Foulds G, et al. Effect of azithromycin (AZM) on the pharmacokinetics of didanosine. (Abstr. 4.29.) 3rd International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, Portugal, 1996.
87. Foulds G, Willavize SV, Luke DR, Stretcher BN, Trapnell CB. Effect of concomitant azithromycin (AZM) on the pharmacokinetics of zidovudine. (Abstr. 4.30.) 3rd International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, Portugal, 1996.
88. Chave JP, Munafo A, Chatton JY, Dayer P, Glauser MP, Biollaz J. Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. Antimicrob Agent Chemother. 36:1992;1013-1018.
89. Vincent J, Foulds G, Apseloff G, Laboy-Goral L, Gerber N. Interaction of rifabutin (RIF) with the macrolides azithromycin (AZM) and clarithromycin (CLA). (Abstr. A29.) 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996.
90. Rapeport WG, Dewland PM, Muirhead DC, Forster PL. Lack of interaction between azithromycin and carbamazepine. Br J Clin Pharmacol. 30:1992;551.
91. Gardner MJ, Coates PE, Hilligoss DM, Henry EB. Lack of effect of azithromycin (AZ) on the pharmacokinetics (PK) of theophylline (T) in man. (Abstr. 410.) 8th Mediterranean Congress of Chemotherapy, Athens, Greece, 1992.
92. Gomez E, Sanchez JE, Aguado S, Alvarez Grande J. Interaction between azithromycin and cyclosporin? Nephron. 73:((Letter.)):1996;724.
93. Backman JT, Olkkola KT, Neuvonen PJ. Azithromycin does not increase plasma concentrations of oral midazolam. Int J Clin Pharmacol Ther. 33:1995;356-359.
94. Zimmermann T, Yeates RA, Laufen H, Scharf F, Leitold M, Wildfeuer A. Influence of the antibiotics erythromycin and azithromycin on the pharmacokintics and pharmacodynamics of midazolam. Arzneimforschung/Drug Res. 46:1996;213-217.
95. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther. 58:1995;310-315.
96. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest. 7:1994;148-156.
97. Foulds G, Luke DR, Teng R, Willavize SA, Friedman H, Curatolo WJ. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother. 37:((suppl C)):1996;37-44.
98. Luke DR, Foulds G, Cohen SF, Levy B. Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother. 40:1996;2577-2581.
99. Zimmermann T, Riedel K-D, Laufen H, Treadway G, Liu J, Wildfeuer A. Intravenous toleration of azithromycin in comparison to clarithromycin and erythromycin. (Abstr. A82.) 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996.
100. Foulds G, Luke DR, Willavize SA, et al. The effect of food and formulation on the bioavailability of azithromycin. (Abstr. 4.23.) 3rd International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, Portugal, 1996.
101. Dunne MW, Havlir D, Dube M, et al. Prevention of Pneumocystis carinii pneumonia with azithromycin. (Abstr. Tu.B.410.) 11th International Conference on AIDS, Vancouver, British Columbia, 1996.
102. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agent Chemother. 39:1995;577-585.
103. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother. 40:1996;1817-1824.
104. Eady EA, Ross JI, Tipper JL, Walters CE, Cove JH, Noble WC. Distribution of genes encoding erythromycin ribosomal methylases and an erythromycin efflux pump in epidemiologically distinct groups of staphylococci. J Antimicrob Chemother. 31:1993;211-217.
105. Clancy J, Petitpas J, Dib-Hajj F, et al. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Molec Microbiol. 22:1996;869-879.
106. Tebas P, Sultan F, Wallace RJ Jr, Frazer V. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis. 20:1995;443-444.
107. Meier A, Heifets L, Wallace RJ Jr, et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observations of multiple 23S rDNA mutations in a clonal population. J Infect Dis. 174:1996;354-360.
108. Wallace RJ Jr, Meier A, Brown BA, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother. 40:1996;1676-1681.
109. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 1995;44:1-34.
110. Pierce M, Crampton S, Henry D, Craft S, Notario G. The effect of MAC and its prevention on survival in patients with advanced HIV infection. (Late Breaker Abstract Book.) 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995.